This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 162 |
middle east | 151 |
east respiratory | 141 |
syndrome coronavirus | 141 |
novel coronavirus | 103 |
lonicerae japonicae | 76 |
japonicae flos | 73 |
growth factor | 72 |
fibroblast growth | 71 |
acute respiratory | 49 |
saudi arabia | 47 |
cov infection | 37 |
authentic lonicerae | 35 |
confirmed covid | 34 |
flos lonicerae | 33 |
confirmed cases | 30 |
avian influenza | 27 |
severe acute | 26 |
coronavirus infection | 24 |
suspected covid | 24 |
coronavirus disease | 24 |
nucleic acid | 23 |
critically ill | 22 |
public health | 22 |
respiratory distress | 18 |
mechanical ventilation | 18 |
lonicera japonica | 17 |
world health | 17 |
south korea | 17 |
coronavirus pneumonia | 17 |
health organization | 17 |
respiratory failure | 17 |
ill patients | 17 |
bile acid | 16 |
spike protein | 16 |
mitogenic fgfs | 16 |
chemical fingerprint | 16 |
respiratory tract | 16 |
chest ct | 15 |
health commission | 15 |
body temperature | 15 |
clinical characteristics | 15 |
national health | 15 |
mers coronavirus | 14 |
neutralizing antibodies | 14 |
convalescent plasma | 14 |
distress syndrome | 14 |
clinical trials | 14 |
hubei province | 14 |
metabolic axis | 14 |
family cluster | 14 |
bile acids | 14 |
fgf axes | 13 |
doc id | 13 |
front med | 13 |
med doi | 13 |
emergency department | 13 |
metabolic fgfs | 13 |
cord uid | 13 |
human coronavirus | 13 |
probable covid | 12 |
severe cases | 12 |
dromedary camels | 12 |
fgf metabolic | 12 |
human transmission | 11 |
chlorogenic acid | 11 |
first case | 11 |
person transmission | 11 |
infectious diseases | 10 |
health care | 10 |
intensive care | 10 |
may also | 10 |
japonica thunb | 10 |
clinical features | 10 |
adipose tissue | 10 |
metabolic homeostasis | 10 |
tested positive | 10 |
control measures | 10 |
ecological system | 10 |
cell proliferation | 10 |
patients infected | 10 |
zhejiang province | 10 |
fgf acts | 10 |
lopinavir ritonavir | 10 |
lower respiratory | 10 |
healthcare workers | 9 |
cov infections | 9 |
close contacts | 9 |
ethics committee | 9 |
suspected cases | 9 |
institutional review | 9 |
disease control | 9 |
insulin resistance | 9 |
case definition | 9 |
research protocol | 9 |
protocol requiring | 9 |
relevant institutional | 9 |
organ failure | 9 |
bundle pharmacotherapy | 9 |
respiratory symptoms | 9 |
requiring approval | 9 |
cov antibodies | 9 |
research team | 9 |
review board | 9 |
receptor binding | 9 |
index case | 9 |
descriptive study | 9 |
traditional chinese | 9 |
novel virus | 8 |
chinese traditional | 8 |
tumoral calcinosis | 8 |
commonly used | 8 |
viral rna | 8 |
different varieties | 8 |
patent medicine | 8 |
glass opacity | 8 |
united arab | 8 |
infectious disease | 8 |
infected pneumonia | 8 |
hplc fingerprint | 8 |
seven patients | 8 |
investigation team | 8 |
respiratory illness | 8 |
chinese herbs | 8 |
severe pneumonia | 8 |
insulin sensitivity | 8 |
binding domain | 8 |
infection control | 8 |
arab emirates | 8 |
family case | 8 |
adipose tissues | 8 |
metabolic effects | 8 |
traditional patent | 7 |
fatty acid | 7 |
severe respiratory | 7 |
like protease | 7 |
component analysis | 7 |
united states | 7 |
rhesus macaques | 7 |
clinical effectiveness | 7 |
nervous system | 7 |
among hcp | 7 |
critical covid | 7 |
endocrine fgf | 7 |
incubation period | 7 |
critical patients | 7 |
fgf levels | 7 |
chinese medicine | 7 |
coexisting conditions | 7 |
blood pressure | 7 |
novel human | 7 |
acquired pneumonia | 7 |
new coronavirus | 7 |
mouse model | 7 |
energy expenditure | 7 |
multiple organ | 7 |
mitogenic fgf | 7 |
weight loss | 7 |
producing areas | 7 |
fat diet | 7 |
metabolic axes | 7 |
fatty liver | 7 |
systematic review | 7 |
upper respiratory | 7 |
clinical symptoms | 7 |
kl klb | 7 |
serologic testing | 7 |
ct scan | 7 |
current situation | 7 |
invasive mechanical | 6 |
arabian peninsula | 6 |
coronavirus infections | 6 |
ncov outbreak | 6 |
medical staff | 6 |
fgf expression | 6 |
therapeutic options | 6 |
close contact | 6 |
oxygen therapy | 6 |
coronavirus middle | 6 |
health emergency | 6 |
ncov infection | 6 |
old male | 6 |
hospitalized patients | 6 |
severe patients | 6 |
pneumonia outbreak | 6 |
quality control | 6 |
cov cases | 6 |
family members | 6 |
pharmacological effects | 6 |
closely related | 6 |
skeletal muscle | 6 |
household contacts | 6 |
diabetes mellitus | 6 |
germplasm resources | 6 |
familial cluster | 6 |
respiratory support | 6 |
metabolic fgf | 6 |
global health | 6 |
epithelial cells | 6 |
cell count | 6 |
genetic diversity | 6 |
coronavirus replication | 6 |
secondary cases | 6 |
tested negative | 6 |
results showed | 6 |
authentic product | 6 |
cell lines | 6 |
dry cough | 5 |
bat origin | 5 |
highly suspected | 5 |
transmission dynamics | 5 |
china novel | 5 |
acid testing | 5 |
familial tumoral | 5 |
structural elements | 5 |
human infections | 5 |
antiviral treatment | 5 |
fatality rate | 5 |
transgenic mice | 5 |
population growth | 5 |
acid test | 5 |
signal axes | 5 |
travel history | 5 |
serum fgf | 5 |
pediatric patients | 5 |
risk assessment | 5 |
moderate patients | 5 |
hepatic fgf | 5 |
fgf promotes | 5 |
including deaths | 5 |
chain reaction | 5 |
membrane fusion | 5 |
glucose uptake | 5 |
widely used | 5 |
ct images | 5 |
hong kong | 5 |
observational study | 5 |
organ dysfunction | 5 |
nasopharyngeal swab | 5 |
pharmacological fgf | 5 |
spike glycoprotein | 5 |
care unit | 5 |
clinical manifestations | 5 |
emergency committee | 5 |
western medicine | 5 |
islet hyperplasia | 5 |
patients admitted | 5 |
parathyroid hormone | 5 |
converting enzyme | 5 |
fgf family | 5 |
virus entry | 5 |
seven cases | 5 |
computed tomography | 5 |
symptoms resolved | 5 |
infectious virus | 5 |
fgf may | 5 |
fgf axis | 5 |
klb complex | 5 |
coronavirus investigating | 5 |
early phase | 5 |
broad spectrum | 5 |
cd cd | 5 |
abdominal pain | 5 |
interorgan crosstalk | 5 |
seven critically | 5 |
noxious substances | 5 |
tissue remodeling | 5 |
viral infections | 5 |
mortality rate | 5 |
arabia middle | 5 |
positive results | 5 |
polymerase chain | 5 |
review article | 5 |
risk factors | 5 |
white blood | 5 |
promote cell | 5 |
care medicine | 5 |
deficient mice | 5 |
ground glass | 5 |
fever clinic | 5 |
infected patients | 5 |
comparative study | 5 |
critical ppe | 4 |
metabolic rate | 4 |
within days | 4 |
type diabetes | 4 |
first patient | 4 |
pneumonia caused | 4 |
chest computed | 4 |
healthcare personnel | 4 |
binding protein | 4 |
endocrine fgfs | 4 |
healthcare settings | 4 |
seafood wholesale | 4 |
heparan sulfate | 4 |
cardiac hypertrophy | 4 |
median time | 4 |
human infection | 4 |
wholesale market | 4 |
active component | 4 |
chinese medical | 4 |
common marmoset | 4 |
nk cells | 4 |
pneumonia associated | 4 |
stress response | 4 |
metabolic tissues | 4 |
dipeptidyl peptidase | 4 |
heart failure | 4 |
local governments | 4 |
coronavirus neutralizing | 4 |
fingerprint chromatogram | 4 |
therapeutic strategies | 4 |
high levels | 4 |
genome sequence | 4 |
test results | 4 |
text database | 4 |
plasma transfusion | 4 |
bone marrow | 4 |
huanan seafood | 4 |
brown adipose | 4 |
informed consent | 4 |
blood cell | 4 |
neutralizing antibody | 4 |
important factor | 4 |
creatine kinase | 4 |
first confirmed | 4 |
clinical trial | 4 |
gas chromatography | 4 |
another study | 4 |
clinical specimens | 4 |
cell entry | 4 |
chronic kidney | 4 |
specific igm | 4 |
kidney disease | 4 |
electron probe | 4 |
clinical practice | 4 |
influenza virus | 4 |
case report | 4 |
intravascular coagulation | 4 |
thereby leading | 4 |
oxidative stress | 4 |
authentic herbs | 4 |
emerging novel | 4 |
acinar cell | 4 |
severe covid | 4 |
morphological characteristics | 4 |
association committee | 4 |
cov replication | 4 |
indicating person | 4 |
epidemic prevention | 4 |
three times | 4 |
extracellular matrix | 4 |
coronavirus outbreak | 4 |
healthcare facilities | 4 |
two patients | 4 |
early transmission | 4 |
swab specimen | 4 |
live poultry | 4 |
immune system | 4 |
three cases | 4 |
kidney injury | 4 |
materia medica | 4 |
inflammatory response | 4 |
acute kidney | 4 |
immune response | 4 |
liver disease | 4 |
infect humans | 4 |
one case | 4 |
acid oxidation | 4 |
positive rate | 4 |
monoclonal antibody | 4 |
spring festival | 4 |
functional receptor | 4 |
liquid chromatography | 4 |
autocrine paracrine | 4 |
viral load | 4 |
cohort study | 4 |
coronavirus emc | 4 |
literature update | 4 |
care facilities | 4 |
creative commons | 4 |
respiratory droplets | 4 |
phosphate wasting | 4 |
interquartile range | 4 |
international concern | 4 |
amino acid | 4 |
inflammatory damage | 4 |
gastrointestinal symptoms | 4 |
contact investigation | 4 |
cleavage site | 4 |
disseminated intravascular | 4 |
chinese materia | 4 |
cov outbreak | 4 |
studies showed | 4 |
coronavirus indicating | 4 |
oxygen saturation | 4 |
coronavirus spike | 4 |
mg day | 4 |
probable bat | 4 |
protective equipment | 4 |
factor protects | 4 |
clinical course | 4 |
outbreak associated | 4 |
animal model | 4 |
time reverse | 4 |
journal full | 4 |
improves outcome | 4 |
viral pneumonia | 4 |
median incubation | 4 |
reproduction number | 4 |
tissues organs | 4 |
noninvasive ventilation | 4 |
geoauthentic lonicerae | 3 |
respiratory disease | 3 |
positive cases | 3 |
epidemiological data | 3 |
cytokine storms | 3 |
fgf gene | 3 |
cases developed | 3 |
multiple tissues | 3 |
coronavirus genomes | 3 |
critical care | 3 |
regulatory element | 3 |
adult patients | 3 |
coronavirus study | 3 |
matrix heparan | 3 |
hyaline membrane | 3 |
human cases | 3 |
red long | 3 |
missed diagnosis | 3 |
care workers | 3 |
highly pathogenic | 3 |
ncov case | 3 |
cell culture | 3 |
hr domains | 3 |
thereby reducing | 3 |
clinical studies | 3 |
rna polymerase | 3 |
metabolic syndrome | 3 |
general dr | 3 |
spectrum antiviral | 3 |
first laboratory | 3 |
wound healing | 3 |
new virus | 3 |
jinyebaidu granules | 3 |
phylogenetic analysis | 3 |
case fatality | 3 |
total number | 3 |
cell membrane | 3 |
two consecutive | 3 |
chinese center | 3 |
reactive protein | 3 |
epidemic situation | 3 |
primate model | 3 |
three years | 3 |
confirmed patients | 3 |
normal levels | 3 |
requiring mv | 3 |
chinese mainland | 3 |
multiple organs | 3 |
unprecedented responses | 3 |
autosomal recessive | 3 |
analysis showed | 3 |
respiratory infections | 3 |
influenza viruses | 3 |
neutralization assay | 3 |
mice lacking | 3 |
secondary transmission | 3 |
second chest | 3 |
three patients | 3 |
peripheral tissues | 3 |
descriptive genomic | 3 |
resolution liquid | 3 |
chinese government | 3 |
viral replication | 3 |
also used | 3 |
fatty acids | 3 |
studies mainly | 3 |
mice developed | 3 |
standard chemical | 3 |
systemic metabolic | 3 |
spectrum antivirals | 3 |
highly similar | 3 |
henan province | 3 |
lonicera macrathodes | 3 |
lymphocyte count | 3 |
health authorities | 3 |
patients presented | 3 |
including fgf | 3 |
death caused | 3 |
emergency response | 3 |
macrathodes hands | 3 |
medical professionals | 3 |
weight heparin | 3 |
respiratory specimens | 3 |
sugar intake | 3 |
also found | 3 |
energy metabolism | 3 |
phase trial | 3 |
pharyngeal swabs | 3 |
cases may | 3 |
one study | 3 |
high mortality | 3 |
herbal medicine | 3 |
patients receiving | 3 |
underlying comorbidities | 3 |
product areas | 3 |
grand dictionary | 3 |
may june | 3 |
moderate covid | 3 |
supplementary material | 3 |
north america | 3 |
pleural effusion | 3 |
critical roles | 3 |
type ii | 3 |
common ward | 3 |
medica grand | 3 |
symptom onset | 3 |
polymorphism analysis | 3 |
human fibroblast | 3 |
coronavirus receptor | 3 |
washington state | 3 |
case investigation | 3 |
extracorporeal membrane | 3 |
muscle wasting | 3 |
controlled trials | 3 |
cause human | 3 |
patients received | 3 |
hands mazz | 3 |
early noninvasive | 3 |
acid biosynthesis | 3 |
shandong province | 3 |
since december | 3 |
authentic producing | 3 |
medical institutions | 3 |
disease progressed | 3 |
personal protective | 3 |
induces fgf | 3 |
length polymorphism | 3 |
significantly higher | 3 |
specific antiviral | 3 |
municipal government | 3 |
interstitial pneumonia | 3 |
tract samples | 3 |
nonhuman primate | 3 |
pcr assays | 3 |
restriction fragment | 3 |
metabolic pathways | 3 |
recently emerged | 3 |
membrane oxygenation | 3 |
consensus statement | 3 |
china cdc | 3 |
virus outbreak | 3 |
septic shock | 3 |
postponing resumption | 3 |
nasal cannula | 3 |
increased levels | 3 |
standardized data | 3 |
target tissues | 3 |
metabolic diseases | 3 |
metabolic regulator | 3 |
patients showed | 3 |
systemic mineral | 3 |
took place | 3 |
mineral balance | 3 |
immune responses | 3 |
anal swabs | 3 |
complications tend | 3 |
renal failure | 3 |
binding affinity | 3 |
interim guidance | 3 |
sequential ventilation | 3 |
spread mainly | 3 |
white adipose | 3 |
rate increased | 3 |
cytokine storm | 3 |
glucocorticoid treatment | 3 |
human angiotensin | 3 |
hospital outbreak | 3 |
abattoir workers | 3 |
scavenging capacities | 3 |
sterol regulatory | 3 |
fragment length | 3 |
second case | 3 |
dna synthesis | 3 |
angiotensin ii | 3 |
infected cells | 3 |
within km | 3 |
emerging middle | 3 |
sequential noninvasive | 3 |
chest tightness | 3 |
plasma therapy | 3 |
health measures | 3 |
laboratory confirmation | 3 |
electron microscopy | 3 |
trueborn flos | 3 |
fat content | 3 |
different regions | 3 |
showed diffuse | 3 |
human disease | 3 |
signaling pathway | 3 |
pharmacotherapy regimen | 3 |
chest imaging | 3 |
least days | 3 |
respiratory samples | 3 |
fgf signal | 3 |
clinical signs | 3 |
jiangsu province | 3 |
chronic hepatitis | 3 |
patients presenting | 3 |
medical association | 3 |
clinical conditions | 3 |
emerging infectious | 3 |
unknown origin | 3 |
novel avian | 3 |
shandong provinces | 3 |
green arrow | 3 |
sporadic cases | 3 |
genomic study | 3 |
hospital admission | 3 |
confirmed case | 3 |
healthcare worker | 3 |
nucleoside analogs | 3 |
full genome | 3 |
derived fgf | 3 |
sampling interval | 3 |
stress damage | 3 |
fgf regulates | 3 |
ncov test | 3 |
membrane formation | 3 |
failure requiring | 3 |
nonstructural proteins | 3 |
therapeutic effects | 3 |
bone health | 3 |
muscle mass | 3 |
patient presented | 3 |
genomic characterisation | 3 |
china clinical | 3 |
hypophosphatemic rickets | 3 |
golgi apparatus | 3 |
mers patients | 3 |
human coronaviruses | 3 |
pathogenic coronavirus | 3 |
study group | 3 |
gum inflammation | 3 |
rapid resolution | 3 |
bat coronaviruses | 3 |
one patient | 3 |
blood urea | 3 |
worst hit | 3 |
virus origins | 3 |
mycophenolic acid | 3 |
dpp receptor | 3 |
tissue damage | 3 |
patient died | 3 |
measures taken | 3 |
previously unknown | 3 |
xiaokun li | 3 |
mitogenic axis | 3 |
nonalcoholic steatohepatitis | 3 |
certified flos | 3 |
hajj pilgrims | 3 |
commons licence | 3 |
two cases | 3 |
mild upper | 3 |
camel sera | 3 |
monoclonal antibodies | 3 |
patchy shadows | 3 |
recently traveled | 3 |
interim case | 3 |
hepatocellular carcinoma | 3 |
missense mutation | 3 |
showed multiple | 3 |
frequently detected | 3 |
innate immune | 3 |
disease progression | 3 |
critical cases | 3 |
fgfs appear | 3 |
respiratory rate | 3 |
serological study | 3 |
metabolic derangements | 3 |
increased serum | 3 |
processing methods | 3 |
used method | 3 |
took care | 3 |
high affinity | 3 |
scan showed | 3 |
cov transmission | 3 |
prolonged fasting | 3 |
genome sequences | 3 |
obese mice | 3 |
fusion core | 3 |
fungal infection | 3 |
urea nitrogen | 3 |
three cultivars | 3 |
quality evaluation | 3 |
successful management | 3 |
secondary infections | 3 |
diabetic cardiomyopathy | 3 |
affected countries | 3 |
intravenous injection | 3 |
wide range | 3 |
reported among | 3 |
ihr emergency | 3 |
reading frames | 3 |
pathological findings | 3 |
invasive ventilation | 3 |
human influenza | 3 |
early stage | 3 |
studies discussed | 3 |
mildly symptomatic | 3 |
inflammatory infiltration | 3 |
within two | 3 |
retrospective study | 3 |
two studies | 3 |
contact history | 3 |
pulmonary edema | 3 |
bat coronavirus | 3 |
blood donors | 3 |
medical team | 3 |
recent outbreak | 3 |
medical records | 3 |
subunit vaccine | 3 |
animal source | 3 |
laboratory testing | 3 |
confirmed based | 2 |
intracellular kinase | 2 |
phase iii | 2 |
unique structural | 2 |
taphozous perforatus | 2 |
viral infectivity | 2 |
exert therapeutic | 2 |
lactate dehydrogenase | 2 |
first honeysuckle | 2 |
higher quality | 2 |
climate factors | 2 |
disease transmission | 2 |
treated using | 2 |
two months | 2 |
plucking time | 2 |
tongji medical | 2 |
signal axis | 2 |
characteristic cytopathic | 2 |
genomic characterization | 2 |
body weight | 2 |
life expectancy | 2 |
fgf signaling | 2 |
production areas | 2 |
china genomic | 2 |
literature database | 2 |
rapidly spread | 2 |
nonalcoholic fatty | 2 |
prone positioning | 2 |
following criteria | 2 |
congestive heart | 2 |
first covid | 2 |
cov spike | 2 |
thereby preventing | 2 |
epidemiology team | 2 |
coronavirus infected | 2 |
attenuate inflammation | 2 |
financial support | 2 |
professional development | 2 |
epo levels | 2 |
newly emerged | 2 |
two samples | 2 |
associated outbreak | 2 |
neutralizing monoclonal | 2 |
cov patients | 2 |
fusion peptide | 2 |
metabolic disorders | 2 |
pathological changes | 2 |
viral entry | 2 |
activities driven | 2 |
medical center | 2 |
increased risks | 2 |
often used | 2 |
biological effects | 2 |
rna genome | 2 |
controlled trial | 2 |
igg antibodies | 2 |
avian populations | 2 |
multiple shedding | 2 |
latest guidelines | 2 |
avian coronaviruses | 2 |
mental status | 2 |
mass index | 2 |
coronavirus originating | 2 |
seasonal influenza | 2 |
huazhong university | 2 |
outbreak occurred | 2 |
antiviral treatments | 2 |
rna virus | 2 |
pathway fibroblast | 2 |
paracrine mitogenic | 2 |
different biological | 2 |
final exam | 2 |
three members | 2 |
ongoing clinical | 2 |
ribavirin improves | 2 |
cumulative number | 2 |
lessons learned | 2 |
highly sensitive | 2 |
adjusted estimation | 2 |
rheumatoid arthritis | 2 |
among pilgrims | 2 |
new cov | 2 |
specific treatment | 2 |
virus isolated | 2 |
randomized clinical | 2 |
oral oseltamivir | 2 |
gradually decreased | 2 |
coronavirus epidemic | 2 |
dependent mechanism | 2 |
antipyretic effect | 2 |
cases included | 2 |
factor action | 2 |
lung disease | 2 |
rrna gene | 2 |
study middle | 2 |
highly contagious | 2 |
samples collected | 2 |
renal proximal | 2 |
deficient diet | 2 |
protein nanoparticles | 2 |
clinical management | 2 |
proliferatoractivated receptor | 2 |
acute renal | 2 |
axis drives | 2 |
healthy individuals | 2 |
shedding routes | 2 |
genuine producing | 2 |
effectively inhibit | 2 |
gene sequence | 2 |
sars coronavirus | 2 |
metabolic perturbations | 2 |
tradit herbal | 2 |
glucose homeostasis | 2 |
infected individuals | 2 |
laboratory findings | 2 |
large outbreaks | 2 |
imaging features | 2 |
new bile | 2 |
ng ml | 2 |
medicine research | 2 |
treat middle | 2 |
vascular calcification | 2 |
open reading | 2 |
medical education | 2 |
will reduce | 2 |
severe illness | 2 |
still unclear | 2 |
coronavirus diseases | 2 |
scientific journal | 2 |
ketogenic diet | 2 |
orphan receptor | 2 |
lung changes | 2 |
peroxisome proliferator | 2 |
nosocomial outbreaks | 2 |
adverse effects | 2 |
fibrous dysplasia | 2 |
confirmatory testing | 2 |
dominant hypophosphatemic | 2 |
autosomal dominant | 2 |
exocrine pancreas | 2 |
february except | 2 |
high prevalence | 2 |
confirmed human | 2 |
early symptoms | 2 |
also described | 2 |
coronavirus isolated | 2 |
increased epo | 2 |
sequence divergence | 2 |
trained staff | 2 |
reverse transcription | 2 |
flow nasal | 2 |
aspergillus flavus | 2 |
sympathetic nervous | 2 |
infiltrating shadows | 2 |
guidelines issued | 2 |
comprehensive review | 2 |
sustained hypoxia | 2 |
serological investigation | 2 |
sichuan province | 2 |
extraction table | 2 |
cell injury | 2 |
several major | 2 |
side effects | 2 |
clinical manifestation | 2 |
cause respiratory | 2 |
alveolar epithelial | 2 |
mers outbreak | 2 |
kz i | 2 |
embryonic development | 2 |
call hereafter | 2 |
aspartate aminotransferase | 2 |
cases suggestive | 2 |
hcp working | 2 |
day survival | 2 |
pneumonia clinical | 2 |
symptoms disappeared | 2 |
paracrine fgf | 2 |
clinical application | 2 |
radiological characteristics | 2 |
laboratory results | 2 |
syncytial cells | 2 |
erasmus medical | 2 |
controlled phase | 2 |
mdck cells | 2 |
volatile oil | 2 |
expressing hdpp | 2 |
like coronavirus | 2 |
median mv | 2 |
producing area | 2 |
nosocomial transmission | 2 |
related orphan | 2 |
biliary cholangitis | 2 |
cannula oxygen | 2 |
governance perspective | 2 |
among confirmed | 2 |
associated outbreaks | 2 |
functional divergence | 2 |
calcium reabsorption | 2 |
acute pneumonia | 2 |
remains low | 2 |
control mechanism | 2 |
metabolic health | 2 |
lung injury | 2 |
mild clinical | 2 |
eventually died | 2 |
inflammatory mediators | 2 |
decreased viral | 2 |
slaughterhouse workers | 2 |
alanine aminotransferase | 2 |
coronavirus antibodies | 2 |
triad complex | 2 |
patients manifested | 2 |
presented fever | 2 |
hospital contacts | 2 |
tract symptoms | 2 |
integrated stress | 2 |
main producing | 2 |
renal dysfunction | 2 |
six days | 2 |
also discussed | 2 |
coronavirus causing | 2 |
evaluating clinical | 2 |
causes familial | 2 |
underlying disease | 2 |
min zhou | 2 |
ebola virus | 2 |
study showed | 2 |
serum levels | 2 |
previous epidemics | 2 |
studies analyzed | 2 |
bactrian camels | 2 |
heavy mental | 2 |
different species | 2 |
whole country | 2 |
processing method | 2 |
common fgf | 2 |
first cluster | 2 |
treatment options | 2 |
acid content | 2 |
unknown cause | 2 |
bilateral patchy | 2 |
fatal outcome | 2 |
method used | 2 |
attenuate stress | 2 |
host cells | 2 |
case series | 2 |
new type | 2 |
block virus | 2 |
study reports | 2 |
pcr tests | 2 |
associated pneumonia | 2 |
involved lung | 2 |
bowel function | 2 |
cholesterol efflux | 2 |
saijuan chen | 2 |
investigation revealed | 2 |
high fat | 2 |
severe middle | 2 |
chinese scientific | 2 |
acid sequence | 2 |
old female | 2 |
protective role | 2 |
protein microarray | 2 |
obesogenic diet | 2 |
response epidemiology | 2 |
hospital outbreaks | 2 |
whereas igg | 2 |
oral ulcer | 2 |
intravenous infusion | 2 |
patients underwent | 2 |
drive effects | 2 |
family contacts | 2 |
highest quality | 2 |
another case | 2 |
first reported | 2 |
poultry market | 2 |
pancreatic fgf | 2 |
tedros adhanom | 2 |
em structure | 2 |
will win | 2 |
lymphoid infiltration | 2 |
sense rna | 2 |
fgf drive | 2 |
metabolic roles | 2 |
coronavirus epidemiological | 2 |
ncov infected | 2 |
glucose reabsorption | 2 |
actual number | 2 |
effective measures | 2 |
treatment protocol | 2 |
quality assessment | 2 |
two weeks | 2 |
days later | 2 |
many cases | 2 |
medical college | 2 |
team also | 2 |
virus spread | 2 |
health emergencies | 2 |
acinetobacter baumannii | 2 |
chest radiograph | 2 |
renal phosphate | 2 |
signaling pathways | 2 |
prone position | 2 |
viral polyproteins | 2 |
studies regarding | 2 |
transmission patterns | 2 |
accessory proteins | 2 |
hospital starting | 2 |
trial version | 2 |
hcp infection | 2 |
hospital patients | 2 |
day methylprednisolone | 2 |
previous experience | 2 |
early sequential | 2 |
gel electrophoresis | 2 |
studies reported | 2 |
unprecedented efforts | 2 |
take oral | 2 |
aerosol inhalation | 2 |
brown fat | 2 |
factor fibroblast | 2 |
initially named | 2 |
cord injury | 2 |
sample nucleic | 2 |
pipistrellus bat | 2 |
acquired phosphate | 2 |
many unanswered | 2 |
scans showed | 2 |
fgf subfamily | 2 |
symptomatic cases | 2 |
infected animals | 2 |
gene source | 2 |
mottled skin | 2 |
core body | 2 |
sequence repeat | 2 |
spread around | 2 |
hubei medical | 2 |
multinucleated syncytial | 2 |
expert group | 2 |
temporal interorgan | 2 |
emerged novel | 2 |
supportive treatment | 2 |
active fgf | 2 |
epidemiologic investigation | 2 |
first identified | 2 |
infrared spectrum | 2 |
camels middle | 2 |
subcutaneous injection | 2 |
treating influenza | 2 |
cov case | 2 |
capital city | 2 |
inflection point | 2 |
also occurred | 2 |
extrahepatic cholestasis | 2 |
tracheal intubation | 2 |
neuraminidase inhibitors | 2 |
current knowledge | 2 |
active components | 2 |
proximal tubule | 2 |
pilgrims returning | 2 |
system support | 2 |
epidemic spread | 2 |
authentic production | 2 |
epidemiological assessment | 2 |
atypical pneumonia | 2 |
sore throat | 2 |
glucose metabolism | 2 |
family clusters | 2 |
rate among | 2 |
antiviral therapy | 2 |
early detection | 2 |
viral infection | 2 |
lymphocyte counts | 2 |
hospital affiliated | 2 |
specific drugs | 2 |
important lessons | 2 |
retrospective cohort | 2 |
liver injury | 2 |
pp ab | 2 |
rapd fingerprint | 2 |
date palm | 2 |
metabolic regulation | 2 |
shandong trueborn | 2 |
retinoic acid | 2 |
initial symptoms | 2 |
causative factor | 2 |
cancer types | 2 |
abnormal coagulation | 2 |
associated mers | 2 |
fgf increases | 2 |
malayan pangolins | 2 |
long time | 2 |
hepatic steatosis | 2 |
state council | 2 |
serum igm | 2 |
digestive tract | 2 |
sequence homology | 2 |
important role | 2 |
brush border | 2 |
human middle | 2 |
functional specifications | 2 |
urban areas | 2 |
postexposure efficacy | 2 |
distal tubules | 2 |
global public | 2 |
online version | 2 |
xiaokun title | 2 |
outside wuhan | 2 |
clinical data | 2 |
serum antibodies | 2 |
ectopic expression | 2 |
adult family | 2 |
mitogenic members | 2 |
subsequent clinical | 2 |
obese patients | 2 |
developed symptoms | 2 |
fgf protects | 2 |
clinical presentation | 2 |
thereby alleviating | 2 |
cell types | 2 |
treatment strategies | 2 |
presented coagulation | 2 |
southern china | 2 |
acute blood | 2 |
er stress | 2 |
recessive familial | 2 |
last three | 2 |
laboratory tests | 2 |
vein thrombosis | 2 |
identified among | 2 |
oral jinyebaidu | 2 |
spectrum antibiotics | 2 |
fatal case | 2 |
herbal drugs | 2 |
revised case | 2 |
cell membranes | 2 |
active role | 2 |
recent years | 2 |
elevated il | 2 |
cardiac injury | 2 |
pulmonary ventilation | 2 |
antipyretic herbal | 2 |
symptoms exist | 2 |
subsequent activation | 2 |
transcriptional control | 2 |
metabolic states | 2 |
ncov spike | 2 |
cell tissue | 2 |
wenzhou people | 2 |
diet induced | 2 |
prefusion conformation | 2 |
clear evidence | 2 |
less susceptible | 2 |
chinese spring | 2 |
mice overexpressing | 2 |
radiograph showed | 2 |
inhibits mers | 2 |
target cells | 2 |
central nervous | 2 |
crosstalk network | 2 |
sclerosing cholangitis | 2 |
research shows | 2 |
diagnostic criteria | 2 |
six months | 2 |
cells exhibited | 2 |
study conducted | 2 |
available data | 2 |
phosphate transport | 2 |
clinical laboratory | 2 |
hcp infections | 2 |
radiological findings | 2 |
air bronchogram | 2 |
geoauthentic herbs | 2 |
patient infected | 2 |
significantly reduced | 2 |
differentiate mers | 2 |
distal renal | 2 |
jkjyh cs | 2 |
heptad repeat | 2 |
tyrosine kinases | 2 |
virological studies | 2 |
french pilgrims | 2 |
whole world | 2 |
per day | 2 |
therapeutic agents | 2 |
smooth muscle | 2 |
etiologic analysis | 2 |
total ash | 2 |
public places | 2 |
dynamic monitoring | 2 |
core structure | 2 |
complex interorgan | 2 |
case reporting | 2 |
poor response | 2 |
tract disease | 2 |
back memories | 2 |
coronavirus treatment | 2 |
related coronaviruses | 2 |
emerging coronaviruses | 2 |
determined via | 2 |
specific rrt | 2 |
water intake | 2 |
liver fat | 2 |
report described | 2 |
unless indicated | 2 |
utmost importance | 2 |
free fatty | 2 |
mesangial cells | 2 |
zhejiang strain | 2 |
rhesus macaque | 2 |
key technology | 2 |
host cell | 2 |
pcr detection | 2 |
cd nk | 2 |
viral titers | 2 |
fgf level | 2 |
right lower | 2 |
negative respiratory | 2 |
consolidation shadow | 2 |
respiratory infection | 2 |
health consequences | 2 |
like ancestor | 2 |
chin tradit | 2 |
human conjunctivitis | 2 |
gene spacer | 2 |
oral liquid | 2 |
db db | 2 |
play critical | 2 |
early january | 2 |
ancestor molecule | 2 |
two decades | 2 |
product area | 2 |
new strain | 2 |
ha gene | 2 |
fat percentage | 2 |
conserved core | 2 |
expressway entrances | 2 |
presented mild | 2 |
higher blood | 2 |
exclusion criteria | 2 |
effective prevention | 2 |
proximal tubules | 2 |
four patients | 2 |
first manifestation | 2 |
honeysuckle peak | 2 |
body mass | 2 |
multiple introduction | 2 |
mice fibroblast | 2 |
later stage | 2 |
treating mers | 2 |
db mice | 2 |
days post | 2 |
fgfs drive | 2 |
mv durations | 2 |
probe method | 2 |
associated comorbidities | 2 |
antimicrobial agents | 2 |
positive airway | 2 |
study ribavirin | 2 |
cases increased | 2 |
ncov pneumonia | 2 |
fgf drives | 2 |
blood loss | 2 |
military support | 2 |
factor regulates | 2 |
heat generation | 2 |
infection prevention | 2 |
circadian behavior | 2 |
free radicals | 2 |
histological examination | 2 |
fgf directly | 2 |
cell survival | 2 |
acid diarrhea | 2 |
imported cases | 2 |
ancestor fgf | 2 |
direct proliferation | 2 |
feb ei | 2 |
icu groups | 2 |
also common | 2 |
ii alveolar | 2 |
peak bbs | 2 |
cov infected | 2 |
lipid droplet | 2 |
early stages | 2 |
also important | 2 |
preliminary epidemiological | 2 |
infections clinical | 2 |
two different | 2 |
white cell | 2 |
using nasopharyngeal | 2 |
chinese strains | 2 |
activated receptor | 2 |
chloroquine effectively | 2 |
apparent heterogeneity | 2 |
health community | 2 |
transcriptase polymerase | 2 |
vaccinia virus | 2 |
general population | 2 |
three days | 2 |
palm orchard | 2 |
obvious adverse | 2 |
medicine shuanghuanglian | 2 |
fatty degeneration | 2 |
virus ankara | 2 |
government convened | 2 |
nadph oxidase | 2 |
first step | 2 |
saudi ministry | 2 |
starvation hormone | 2 |
early prone | 2 |
soil types | 2 |
immune cells | 2 |
alveolar edema | 2 |
least two | 2 |
candida albicans | 2 |
endocrine mode | 2 |
specific igg | 2 |
common symptoms | 2 |
ncov transmission | 2 |
cov investigation | 2 |
five studies | 2 |
solid nodules | 2 |
mainly discussing | 2 |
organ function | 2 |
interferon therapy | 2 |
without obvious | 2 |
probable case | 2 |
lipid catabolism | 2 |
acid synthesis | 2 |
wuhan city | 2 |
oxygen species | 2 |
large healthcare | 2 |
reported outside | 2 |
wenzhou municipal | 2 |
include fever | 2 |
treatment regimen | 2 |
supportive care | 2 |
camel shepherds | 2 |
antibody detection | 2 |
god mountain | 2 |
renal tubular | 2 |
increases energy | 2 |
antibody response | 2 |
patients lived | 2 |
scientific basis | 2 |
high fatality | 2 |
increased lactate | 2 |
airway pressure | 2 |
eastern province | 2 |
center study | 2 |
common ancestor | 2 |
mice expressing | 2 |
treat covid | 2 |
renal tubules | 2 |
face masks | 2 |
primary biliary | 2 |
asymptomatic infection | 2 |
next day | 2 |
system environment | 2 |
induced osteomalacia | 2 |
epidemiological characteristics | 2 |
circulating levels | 2 |
acute cardiac | 2 |
lower total | 2 |
novel strain | 2 |
exposure history | 2 |
virus initially | 2 |
kl complex | 2 |
human betacoronavirus | 2 |
fgf fgf | 2 |
jian xiao | 2 |
induced metabolic | 2 |
pharyngeal swab | 2 |
fungal infections | 2 |
respiratory sample | 2 |
asymptomatic covid | 2 |
pcr testing | 2 |
arabia showed | 2 |
tocilizumab needs | 2 |
cells ruptured | 2 |
lonicerae comparative | 2 |
retrospectively analyzed | 2 |
international health | 2 |
chinese central | 2 |
shuanghuanglian oral | 2 |
patchy ground | 2 |
since february | 2 |
fgf maintains | 2 |
dao wen | 2 |
active calcitriol | 2 |
dysfunction via | 2 |
growth factors | 2 |
infection risks | 2 |
transgenic mouse | 2 |
clinical description | 2 |
promising antivirals | 2 |
oral consent | 2 |
cytopathic effect | 2 |
regulatory activities | 2 |
nerve activity | 2 |
transintestinal flux | 2 |
serological testing | 2 |
metabolic state | 2 |
spinal cord | 2 |
ventricular hypertrophy | 2 |
viral core | 2 |
renal distal | 2 |
reactive oxygen | 2 |
imaging manifestations | 2 |
left lung | 2 |
european society | 2 |
cell cultures | 2 |
invasive mv | 2 |
polyacylamide gel | 2 |
spacer region | 2 |
low pathogenicity | 2 |
factor ameliorates | 2 |
therapeutic efficacy | 2 |
type covid | 2 |
renal injury | 2 |
clinical findings | 2 |
screening assay | 2 |
local tissue | 2 |
ace protein | 2 |
essential role | 2 |
proteolytic processing | 2 |
serologic studies | 2 |
consecutive negative | 2 |
hplc study | 2 |
two trained | 2 |
organismal metabolic | 2 |
transmission rate | 2 |
metabolic activity | 2 |
central china | 2 |
serum glucose | 2 |
fgf classes | 2 |
macranthides hand | 2 |
clinical aspects | 2 |
high serum | 2 |
liver diseases | 2 |
appropriate use | 2 |
preliminary study | 2 |
sequence identity | 2 |
ct values | 2 |
lonicerae study | 2 |
biomedicine literature | 2 |
chinese biomedicine | 2 |
icu stay | 2 |
cov symptoms | 2 |
mainly discussed | 2 |
physiological level | 2 |
medical supplies | 2 |
beneficial effects | 2 |
protecting healthcare | 2 |
metabolic activities | 2 |
children admitted | 2 |
emerging human | 2 |
isolation ward | 2 |
medical care | 2 |
colonic transit | 2 |
rural areas | 2 |
central register | 2 |
muscle pain | 2 |
pandemic potential | 2 |
origin coronavirus | 2 |
thereby contributing | 2 |
coronavirus inhibition | 2 |
disease severity | 2 |
authorized users | 2 |
probable cases | 2 |
induced fibrogenesis | 2 |
first evidence | 2 |
inhibits macrophage | 2 |
temperature reached | 2 |
wasting disorders | 2 |
randomized trial | 2 |
new structural | 2 |
first death | 2 |
pneumonia emergency | 2 |
acquired infections | 2 |
syncytium formation | 2 |
reported including | 2 |
coronavirus hku | 2 |
results suggested | 2 |
wenzhou governance | 2 |
macaque model | 2 |
press conference | 2 |
age years | 2 |
significant threat | 2 |
comparative experiments | 2 |
factor levels | 2 |
medicine shl | 2 |
releasing factor | 2 |
cardiac stress | 2 |
short period | 2 |
still many | 2 |
illness associated | 2 |
limited person | 2 |
induced obesity | 2 |
coronavirus mers | 2 |
patients may | 2 |
klebsiella pneumoniae | 2 |
white lung | 2 |
cellular receptor | 2 |
cochrane central | 2 |
modified vaccinia | 2 |
metabolic functions | 2 |
ruptured within | 2 |
fingerprint atlas | 2 |
fgf activates | 2 |
immune function | 2 |
pancreas secretagogue | 2 |
helix bundle | 2 |
polyproteins pp | 2 |
endoplasmic reticulum | 2 |
factor reduces | 2 |
improves insulin | 2 |
factor increases | 2 |
see table | 2 |
ct scans | 2 |
peroxisome proliferatoractivated | 2 |
induced pancreatitis | 2 |
legal guardians | 2 |
mv duration | 2 |
predictive signs | 2 |
widely recognized | 2 |
biological specimens | 2 |
primary cases | 2 |
data extraction | 2 |
including wat | 2 |
replication cycle | 2 |
later stages | 2 |
five patients | 2 |
control study | 2 |
adhanom ghebreyesus | 2 |
intercellular spaces | 2 |
gastric bypass | 2 |
tissue homeostasis | 2 |
nasal mucosa | 2 |
dependent rna | 2 |
sympathetic nerve | 2 |
study using | 2 |
virus infection | 2 |
acid tests | 2 |
virus circulating | 2 |
paracrine mode | 2 |
potentially enhanced | 2 |
postprandial serum | 2 |
intermediate host | 2 |
peribronchial lymphoid | 2 |
china first | 2 |
multiple hospitals | 2 |
suspected case | 2 |
daily necessity | 2 |
superior quality | 2 |
also known | 2 |
specific primers | 2 |
fgf exhibit | 2 |
china national | 2 |
china association | 2 |
median age | 2 |
two articles | 2 |
germplasm resource | 2 |
icu admission | 2 |
prothrombin time | 2 |
flos research | 2 |
extremely high | 2 |
sodium reabsorption | 2 |
infection therapeutic | 2 |
private hospital | 2 |
documented exposure | 2 |
positive qrt | 2 |
good news | 2 |
receiving corticosteroids | 2 |
important roles | 2 |
clinical update | 2 |
quality among | 2 |
like molecule | 2 |
fgf analog | 2 |
current treatment | 2 |
active constituents | 2 |
unanswered questions | 2 |
candida glabrata | 2 |
total body | 2 |
time rt | 2 |
novel viruses | 2 |
diurnal bile | 2 |
chen declare | 2 |
latest advancements | 2 |
hepatic fatty | 2 |
cause damage | 2 |
like symptoms | 2 |
ventilation algorithm | 2 |
data collection | 2 |
high risk | 2 |
bone fgf | 2 |
healthcare system | 2 |
scientific data | 2 |
another report | 2 |
specimens positive | 2 |
pituitary gland | 2 |
cardiovascular disease | 2 |
support hubei | 2 |
medical observation | 2 |
coagulation function | 2 |
drug development | 2 |
chinese journal | 2 |
another important | 2 |
deep vein | 2 |
factor gene | 2 |
combating covid | 2 |
direct contact | 2 |
key point | 2 |
fgf analogs | 2 |
increased circulating | 2 |
patients requiring | 2 |
driven metabolic | 2 |
coagulation disorders | 2 |
false positive | 2 |
syrian hamsters | 2 |
critical illness | 2 |
reverses hepatic | 2 |
perforatus bat | 2 |
brought back | 2 |
pao fio | 2 |
novel influenza | 2 |
days apart | 2 |
left ventricular | 2 |
hormone fgf | 2 |
multiple signal | 2 |
genetic relationship | 2 |
kinase domains | 2 |
bilateral lung | 2 |
mtor signaling | 2 |
definition middle | 2 |
staff using | 2 |
plasma membrane | 2 |
detected pathogen | 2 |